Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hematologic Neoplasms × alectinib × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 3 Neoplasms 2 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Rare Tumour 1 Rare Tumor 1 Hematologic Neoplasms 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 33 fludarabine 29 Tacrolimus 23 Whole-Body Irradiation 22 Mycophenolic Acid 21 Busulfan 20 fludarabine phosphate 18 Melphalan 16 thymoglobulin 14 Antilymphocyte Serum 14 Thiotepa 11 Methotrexate 11 Stem Cell Transplantation 7 Rituximab 7 Granulocyte Colony-Stimulating Factor 7 Sirolimus 6 Filgrastim 6 trametinib 5 ruxolitinib 4 merphos 4 Nivolumab 4 Cytarabine 4 Cyclosporine 4 Cord Blood Stem Cell Transplantation 4 fedratinib 3 ceritinib 3 Radiotherapy 3 Peripheral Blood Stem Cell Transplantation 3 Pentostatin 3 Mesna 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05159245 2024-07-15

FINPROVE

Helsinki University Central Hospital

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡